AstraZeneca plc (LON:AZN) announced a dividend on Friday, February 2nd, Upcoming.Co.Uk reports. Investors of record on Thursday, February 15th will be paid a dividend of GBX 133.60 ($1.85) per share by the biopharmaceutical company on Monday, March 19th. This represents a yield of 2.8%. The ex-dividend date of this dividend is Thursday, February 15th. This is a positive change from AstraZeneca’s previous dividend of $68.90. The official announcement can be accessed at this link.

Shares of AstraZeneca (AZN) opened at GBX 4,822 ($66.62) on Wednesday. The stock has a market cap of $60,820.00 and a price-to-earnings ratio of 2,819.88. AstraZeneca has a fifty-two week low of GBX 4,260 ($58.86) and a fifty-two week high of GBX 5,520 ($76.26).

In related news, insider Philip A. J. Broadley acquired 415 shares of the business’s stock in a transaction dated Friday, February 2nd. The stock was acquired at an average price of GBX 4,846 ($66.95) per share, with a total value of £20,110.90 ($27,785.16).

A number of brokerages recently issued reports on AZN. Cfra set a GBX 4,800 ($66.32) price objective on shares of AstraZeneca and gave the stock a “neutral” rating in a report on Friday, February 9th. Berenberg Bank upped their price objective on shares of AstraZeneca from GBX 5,800 ($80.13) to GBX 6,000 ($82.90) and gave the stock a “buy” rating in a report on Thursday, February 8th. JPMorgan Chase & Co. set a GBX 5,500 ($75.99) price objective on shares of AstraZeneca and gave the stock a “buy” rating in a report on Thursday, February 8th. UBS Group set a GBX 4,550 ($62.86) price objective on shares of AstraZeneca and gave the stock a “neutral” rating in a report on Tuesday, February 6th. Finally, Kepler Capital Markets upped their price objective on shares of AstraZeneca from GBX 5,250 ($72.53) to GBX 5,300 ($73.22) and gave the stock a “buy” rating in a report on Tuesday, February 6th. Four equities research analysts have rated the stock with a sell rating, seven have given a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus price target of GBX 5,211.65 ($72.00).

WARNING: This news story was originally published by TheOlympiaReport and is owned by of TheOlympiaReport. If you are accessing this news story on another site, it was illegally copied and reposted in violation of US & international copyright and trademark law. The correct version of this news story can be accessed at https://theolympiareport.com/2018/02/14/astrazeneca-plc-azn-declares-dividend-increase-gbx-133-60-per-share.html.

About AstraZeneca

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Dividend History for AstraZeneca (LON:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.